A Global Prospective Observational Registry of Patients With Pompe Disease

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

December 20, 2034

Study Completion Date

December 20, 2034

Conditions
Pompe Disease
Interventions
BIOLOGICAL

Cipaglucosidase alfa

Enzyme Replacement Therapy (ERT) via intravenous infusion

DRUG

Miglustat

Participants received ATB200 co-administered with AT2221 (Miglustat)

BIOLOGICAL

Alglucosidase alfa or Avalglucosidase alfa

Patients prescribed other commercially available ERT after local regulatory approval

OTHER

Untreated

Patients who are not currently receiving any medical therapy for Pompe disease.

Trial Locations (40)

1000

NOT_YET_RECRUITING

University Medical Centre Ljubljana, Institute of Clinical Neurophysiology, Ljubljana

1090

NOT_YET_RECRUITING

Medizinische Universitaet Wien, Vienna

3000

RECRUITING

Laboratory for Muscle Diseases and Neuropathies, Leuven

6722

NOT_YET_RECRUITING

University of Szeged, Szent-Györgyi Albert Clinical Center, Szeged

7622

NOT_YET_RECRUITING

University of Pécs, Pécs

8000

RECRUITING

Aarhus Universitets hospital, Aarhus C

10017

RECRUITING

NYU Neurogenetics, NYU Langone Medical Center, New York

10126

NOT_YET_RECRUITING

Department of Neurosciences Rita Levi Montalcini, University of Torino, Torino

15219

RECRUITING

University of Pittsburgh, Pittsburgh

15224

RECRUITING

UPMC Children's Hospital of Pittsburgh, Pittsburgh

19104

RECRUITING

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia

22030

RECRUITING

Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax

27710

RECRUITING

Duke University Medical Center, Durham

30322

RECRUITING

Emory University, Atlanta

32207

RECRUITING

Wolfson Children's Hospital, Jacksonville

33100

NOT_YET_RECRUITING

Regional Coordinating Centre for Rare Diseases, university Hospital of Udine, Udine, Italy, Udine

35043

RECRUITING

Universitätsklinikum Gießen und Marburg GmhH, Marburg

44791

RECRUITING

Ruhr-Universität Bochum im St. Josef-Hospital, Bochum

45219

RECRUITING

University of Cincinnati Medical Center, Cincinnati

45229

RECRUITING

Cincinnati Children's Hospital, Cincinnati

46202

RECRUITING

Indiana University, IU Health Physicians Neurology, Indianapolis

63110

RECRUITING

Washington University School of Medicine, St Louis

70124

NOT_YET_RECRUITING

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari

72205

RECRUITING

University of Arkansas Medical Science, Little Rock

80131

NOT_YET_RECRUITING

Centre of Expertise for muscular diseases and peripheral neuropathies European Reference Network for Rare Neuromuscular Diseases, Napoli

80336

NOT_YET_RECRUITING

Universitat Munchen - Friedrich Baur Institut, München

84108

NOT_YET_RECRUITING

University of Utah, Salt Lake City

89081

NOT_YET_RECRUITING

Universitaetsklinikum Ulm, Ulm

92697

RECRUITING

University of California Irvine, Irvine

115228

NOT_YET_RECRUITING

Eginition Hospital, Athens

265239

RECRUITING

SphinCS, Institute of Clinical Science in LSD, Höchheim

3015 GD

NOT_YET_RECRUITING

Dept of Pediatrics Erasmus MC - Sophia Children's Hospital, Rotterdam

35-055

NOT_YET_RECRUITING

entrum Medyczne Medyk, Rzeszów

B15 2TH

RECRUITING

Queen Elizabeth Hospital Birmingham, Birmingham

CB20QQ

RECRUITING

Cambridge University - Addenbrooke's Hospital, Cambridge

CF14 4XW

NOT_YET_RECRUITING

University Hospital of Wale, Cardiff, Cardiff

WC1N 3BG

RECRUITING

National Hospital for Neurology and Neurosurgery, London

WC1N 3JH

RECRUITING

Great Ormond Street Hospital NHS Foundation Trust, London

NW3 2QG

RECRUITING

Royal Free Hospital NHS Foundation Trust, Manchester

M6 8HD

RECRUITING

Salford Royal NHS Foundation Trust, Salford

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY